Skip to main content

Table 3 Prognostic factors of OS of patients with DLBCL

From: Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma

 

Univariate analysis

Multivariate analysis1

 

P

HR (95%CI)

P

HR (95%CI)

MYC EC

0.003

4.694 (1.697–12.988)

0.002

8.068 (2.145–30.348)

MYC R

0.015

3.831 (1.302–11.277)

0.028

8.005 (1.248–51.359)

MYC expression

0.290

1.590 (0.674–3.752)

0.956

1.035 (0.307–3.491)

BCL2 EC

0.037

2.819 (1.063–7.472)

0.172

2.901 (0.629–13.373)

BCL2 R

0.180

2.224 (0.691–7.155)

0.106

0.089 (0.005–1.676)

BCL2 expression

0.390

1.614 (0.542–4.806)

0.624

0.696 (0.163–2.966)

BCL6 EC

0.517

1.461 (0.465–4.592)

0.434

1.683 (0.457–6.195)

BCL6 R

0.039

2.724 (1.049–7.069)

0.550

1.454 (0.426–4.962)

BCL6 expression

0.585

0.768 (0.297–1.981)

0.813

1.174 (0.310–4.446)

Atypical DHL/THL

0.001

9.054 (2.549–32.167)

0.385

2.841 (0.269–29.957)

DHL/THL

0.004

7.011 (1.866–26.342)

0.463

3.111 (0.150–64.521)

DEL

0.740

1.228 (0.366–4.124)

0.825

0.809 (0.123–5.304)

Age

0.860

0.930 (0.417–2.077)

0.442

2.167 (0.301–15.592)

R-CHOP vs R-CHOPE & R-EPOCH

0.731

0.840 (0.310–2.273)

0.080

0.266 (0.061–1.169)

IPI ≥ 3

0.021

3.618 (1.215–10.770)

0.323

0.223 (0.011–4.367)

Marrow involvement

0.007

3.463 (1.415–8.475)

0.011

4.163 (1.436–12.453)

Ann Arbor stage > 2

0.044

7.926 (1.061–59.198)

0.279

3.704(0.345–39.721)

Extranodal sites ≥2

0.044

2.807(1.027–7.678)

0.599

0.603(0.091–3.977)

Elevated LDH

0.050

2.610(0.999–6.819)

0.260

2.470(0.512–11.920)

  1. DLBCL Diffuse large B-cell lymphoma, EC extra copies, R rearrangement, DHL double hit lymphoma, THL triple hit lymphoma, DEL double expressor lymphoma, IPI international prognostic index, LDH lactate dehydrogenase